Mesoblast Financial Statements From 2010 to 2026

MESO Stock  USD 19.17  0.49  2.62%   
Mesoblast's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Mesoblast's valuation are provided below:
Gross Profit
-22.7 M
Market Capitalization
1.9 B
Enterprise Value Revenue
123.2524
Revenue
17.2 M
Earnings Share
(0.85)
We have found one hundred twenty available fundamental ratios for Mesoblast, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mesoblast's last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 28th of January 2026, Market Cap is likely to drop to about 1.3 B. In addition to that, Enterprise Value is likely to drop to about 1.2 B

Mesoblast Total Revenue

15.39 Million

Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 M, Interest Expense of 27.7 M or Selling General Administrative of 20.8 M, as well as many indicators such as Price To Sales Ratio of 79.18, Dividend Yield of 0.0 or PTB Ratio of 2.28. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Build AI portfolio with Mesoblast Stock
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Mesoblast Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets596.4 M902.4 M705.3 M
Pretty Stable
Other Current Liabilities32.3 M30.7 M17 M
Slightly volatile
Total Current Liabilities123.9 M118 M60.8 M
Slightly volatile
Total Stockholder Equity430.9 M687.1 M512.2 M
Slightly volatile
Property Plant And Equipment Net3.8 M6.7 M4.8 M
Slightly volatile
Accounts Payable15 M21.9 M18.4 M
Pretty Stable
Cash194.6 M185.3 M83.4 M
Slightly volatile
Non Current Assets Total474.8 M667.4 M568.3 M
Pretty Stable
Cash And Short Term Investments194.6 M185.3 M83.4 M
Slightly volatile
Net Receivables18 M17.1 MM
Slightly volatile
Common Stock Shares Outstanding69.5 M138.9 M71.3 M
Slightly volatile
Liabilities And Stockholders Equity596.4 M902.4 M705.3 M
Pretty Stable
Other Current Assets5.2 M5.5 M58 M
Slightly volatile
Other Stockholder Equity80.3 M84.5 M343.8 M
Pretty Stable
Total Liabilities165.5 M215.3 M193.1 M
Pretty Stable
Property Plant And Equipment Gross29 M27.6 M12.1 M
Slightly volatile
Total Current Assets121.6 M235 M136.9 M
Very volatile
Accumulated Other Comprehensive Income120.1 M114.4 M67.7 M
Slightly volatile
Intangible Assets358.9 M503 M432.1 M
Pretty Stable
Non Current Liabilities Total116.4 M76.2 M135.5 M
Slightly volatile
Good Will147.7 M154.6 M136.2 M
Slightly volatile
Non Currrent Assets Other1.7 M1.2 MM
Pretty Stable
Short Term Debt68.6 M65.4 M34.5 M
Slightly volatile
Common Stock1.1 B1.7 B981 M
Slightly volatile
Common Stock Total Equity939.2 M1.3 B936.6 M
Slightly volatile
Short Term Investments2.6 M2.9 M3.1 M
Slightly volatile
Other Liabilities16.3 M17.2 M73.5 M
Slightly volatile
Other AssetsM2.1 M2.5 M
Slightly volatile
Property Plant EquipmentM7.5 M5.5 M
Slightly volatile
Deferred Long Term Liabilities75.7 M44.4 M87.4 M
Slightly volatile
Long Term Investments1.5 M1.2 M1.9 M
Slightly volatile
Net Invested Capital674.3 M827.2 M595.3 M
Slightly volatile
Net Working Capital122.8 M117 M46.9 M
Slightly volatile
Short and Long Term Debt Total112.2 M147.4 M87.7 M
Slightly volatile
Long Term Debt80.8 M77.9 M68.3 M
Slightly volatile
Long Term Debt Total69.7 M77.4 M64.3 M
Slightly volatile
Short and Long Term Debt51.2 M48.7 M44.3 M
Slightly volatile
Capital Stock1.3 B1.7 B1.1 B
Slightly volatile
Capital Lease Obligations6.7 M5.6 M8.9 M
Slightly volatile

Mesoblast Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.7 M7.4 M3.2 M
Slightly volatile
Selling General Administrative20.8 M26.7 M24.4 M
Pretty Stable
Total Revenue15.4 M15.5 M18.1 M
Slightly volatile
Other Operating Expenses73.7 M91.6 M88 M
Pretty Stable
Research Development37.9 M40 M44.4 M
Pretty Stable
Total Operating Expenses71.3 M85.7 M84.8 M
Very volatile
Selling And Marketing Expenses17.8 M14.5 M21.5 M
Pretty Stable
Cost Of Revenue5.6 M5.9 M34.1 M
Very volatile
Non Recurring49.5 M55.7 M60.8 M
Slightly volatile
Reconciled Depreciation4.3 M7.4 M3.8 M
Slightly volatile
Interest Income4.3 M4.1 M1.1 M
Slightly volatile

Mesoblast Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation26.7 M25.4 M10.1 M
Slightly volatile
Depreciation7.7 M7.4 M3.3 M
Slightly volatile
Capital Expenditures624.1 K657 K3.3 M
Slightly volatile
End Period Cash Flow108 M185.8 M118.2 M
Pretty Stable
Begin Period Cash Flow102.6 M72.4 M115.1 M
Slightly volatile
Sale Purchase Of Stock45.8 M34.8 M30.5 M
Slightly volatile
Issuance Of Capital Stock93.8 M185.4 M65.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio79.1883.3596.4936
Slightly volatile
PTB Ratio2.282.42.5283
Slightly volatile
Days Sales Outstanding345363266
Slightly volatile
Book Value Per Share0.530.470.7992
Slightly volatile
Average Payables1.3 M1.2 M1.1 M
Very volatile
Stock Based Compensation To Revenue1.41.480.7402
Slightly volatile
Capex To Depreciation0.120.135.1771
Slightly volatile
PB Ratio2.282.42.5283
Slightly volatile
EV To Sales77.0881.1493.8734
Slightly volatile
Payables Turnover0.230.241.9119
Pretty Stable
Sales General And Administrative To Revenue1.471.552.2535
Pretty Stable
Research And Ddevelopement To Revenue2.212.334.0218
Very volatile
Capex To Revenue0.04640.04880.2334
Slightly volatile
Cash Per Share0.0880.130.109
Very volatile
Days Payables Outstanding1.3 K1.2 K500
Slightly volatile
Income Quality0.420.442.0507
Pretty Stable
Intangibles To Total Assets0.460.660.7323
Pretty Stable
Current Ratio2.182.292.9484
Slightly volatile
Receivables Turnover1.261.33141
Slightly volatile
Shareholders Equity Per Share0.530.470.7992
Slightly volatile
Debt To Equity0.150.190.1559
Slightly volatile
Capex Per Share7.0E-47.0E-40.0059
Slightly volatile
Average ReceivablesM5.7 MM
Slightly volatile
Revenue Per Share0.01650.01730.0305
Slightly volatile
Interest Debt Per Share0.07290.120.1056
Slightly volatile
Debt To Assets0.120.150.1197
Slightly volatile
Graham Number1.531.721.8741
Slightly volatile
Price Book Value Ratio2.282.42.5283
Slightly volatile
Days Of Payables Outstanding1.3 K1.2 K500
Slightly volatile
Ebt Per Ebit1.321.881.2218
Slightly volatile
Company Equity Multiplier1.051.181.3336
Slightly volatile
Long Term Debt To Capitalization0.0960.09170.1092
Slightly volatile
Total Debt To Capitalization0.130.160.1333
Slightly volatile
Debt Equity Ratio0.150.190.1559
Slightly volatile
Quick Ratio1.942.042.1414
Slightly volatile
Net Income Per E B T0.730.90.845
Very volatile
Cash Ratio1.721.811.6812
Slightly volatile
Days Of Sales Outstanding345363266
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.171.1357
Slightly volatile
Price To Book Ratio2.282.42.5283
Slightly volatile
Fixed Asset Turnover3.233.47.3887
Slightly volatile
Debt Ratio0.120.150.1197
Slightly volatile
Price Sales Ratio79.1883.3596.4936
Slightly volatile
Asset Turnover0.04530.02520.027
Pretty Stable
Price Fair Value2.282.42.5283
Slightly volatile

Mesoblast Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B1.4 B1.1 B
Slightly volatile
Enterprise Value1.2 B1.4 B1.1 B
Slightly volatile

Mesoblast Fundamental Market Drivers

Forward Price Earnings454.5455
Cash And Short Term Investments161.2 M

Mesoblast Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
23rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as revenue or net income, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.8 MM
Total Revenue15.5 M15.4 M
Cost Of Revenue5.9 M5.6 M
Stock Based Compensation To Revenue 1.48  1.40 
Sales General And Administrative To Revenue 1.55  1.47 
Research And Ddevelopement To Revenue 2.33  2.21 
Capex To Revenue 0.05  0.05 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(3.27)(3.43)

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mesoblast Stock

  0.79VNDA Vanda PharmaceuticalsPairCorr

Moving against Mesoblast Stock

  0.52DRMA Dermata TherapeuticsPairCorr
  0.47AMRN Amarin PLCPairCorr
  0.45SLN Silence Therapeutics PLC Downward RallyPairCorr
  0.42FSTF First State FinancialPairCorr
  0.34PPBT Purple BiotechPairCorr
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.85)
Revenue Per Share
0.14
Quarterly Revenue Growth
4.586
Return On Assets
(0.05)
Return On Equity
(0.19)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.